Theseus Pharmaceuticals is laying off 72% of its staff and exploring potential deals after its lead cancer drug revealed dose-limiting toxicities. The firm anticipates $5.5m in severance costs to be incurred this quarter. Despite the layoffs, Theseus still plans to further develop its pipeline, which could include treatments for lung cancer and other forms of gastrointestinal cancer.
Ransomware Gangs Seek Pen Testers to Boost Quality
Ransomware groups and cybercriminal organisations are hiring cybersecurity professionals to create ransomware and improve their existing attack tools, according to a report by Cato Networks.
